ORIGINAL ARTICLE

IMPACT OF COVID-19 PANDEMIC ON ST-SEGMENT-ELEVATION MYOCARDIAL INFARCTION ADMISSIONS AND OUTCOME IN THE NORTH OF IRAN

Salman Nikfarjam1, Arsalan Salar1, Fardin Mirbolouk1, Azin Vakilpour1, Soheil Hassanipour2, Elham Ramezanzadeh3, Roya Alimoradi1, Aboozarak Fakhr Mousavi1, Jalal Kheirkhah1

1Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, Guilan University of Medical Sciences, Rasht, Iran, 2Gastrointestinal & liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran, 3Razi Clinical Research Development Center, Guilan University of Medical Sciences, Rasht, Iran

Objectives: To determine the incidence of ST-Elevation myocardial infarction (STEMI), patterns of care, and outcomes during the COVID-19 era in a hot-spot region.

Methodology: From February to April 2020, all the STEMI patients were recruited and compared with the STEMI patients in the equivalent period of the previous year. Demographic and clinical information, coronary angiography data, and in-hospital mortality were collected and compared with the non-COVID-19 group. All data analysis was done using IBM SPSS version 20.

Results: There was found a 40% reduction in STEMI admissions during the COVID-19 era compared to the equivalent period in 2019 (55 vs. 92, Rate Ratio (RR): 0.60, 95% CI, 0.49-0.70, p<0.001). Compared with the pre-COVID-19 study group, STEMI patients hospitalized during the pandemic were significantly younger (mean age: 56.10 in 2020 vs. 60.83 in 2019 p=0.012). The percentage of primary percutaneous coronary intervention referral was significantly higher than the previous year (47.8% vs. 75.9% p=0.001). In-hospital death occurred in 4 (4.4%) of STEMI patients admitted before the COVID-19 time, while none of the COVID-19 period studied cases died in hospital (p=0.298).

Conclusion: Admissions for STEMI were substantially reduced during the COVID-19 pandemic. No changes in overall in-hospital mortality or quality indicators were detected.

Keywords: myocardial infarction, COVID-19, coronavirus, admission rate, ST-elevation myocardial infarction

INTRODUCTION

Since December 2019 world has been facing a new critical health challenge known as the COVID-19 pandemic caused by the novel SARS-CoV-2 virus. This pathogen has been responsible for a type of pneumonia that first emerged in Wuhan, China. In addition to China, the U.S., and some European countries, including Italy, Germany and Spain, Iran has been encountering the heaviest burden of the COVID-19 outbreak. The epidemic began in Iran when the first death associated with COVID-19 was detected on February 19, 2020, in Qom, in central Iran. Subsequently, in a short period of time, the infection spread extensively to every other province of the country. The COVID-19 disease has a wide spectrum of clinical signs and symptoms ranging from asymptomatic infection, mild upper respiratory tract disease, severe viral pneumonia, respiratory failure, and even death. Cardiovascular complications commonly occur in Covid-19 patients, with challenges in acute management. Furthermore, this infectious disease has a significant implication on patients' cardiovascular care and increases the risk of serious illness and death in patients with underlying cardiovascular diseases (CVD). With the increasing prevalence of infectious outbreaks in the community, the subsequent worries and anxieties have a considerable psychological impact on the general population regarding seeking medical facilities and can affect various parts of the health care system, including the rate and care of emergency admissions as well. Of note, some surveys have indicated a substantial decline in the number of patients presenting with acute coronary syndrome as well as the number of emergency coronary interventions in the time of the COVID-19 pandemic. Also, the notable influence of this highly contagious coronavirus on the admission incidence of different diseases, particularly acute myocardial infarction, has been indicated in a vast body of literature. This influence in several countries, including the USA and France, has been seen as a decrease in ST-segment elevation myocardial
infarction hospitalizations varying from 18% to 48%, while estimates for certain areas in Spain and Italy reached even to 80%.

These reports contrast the anticipated rise in myocardial infarction rate associated with COVID-19 due to its remarkable impact on the cardiovascular system. For instance, it has been recognized that COVID-19 can aggravate heart damage and lead to a number of cardiovascular complications, including arrhythmia, acute myocardial injury, myocarditis, venous thromboembolism and heart failure. Also the treatment used to manage the disease itself is associated with cardiovascular side effects. The possible causes and explanations regarding the drop in myocardial infarction admissions rate during COVID-19 pandemic are not yet fully explained. To the best of our knowledge, limited data about the effects of recent pandemic on the admission rate of patients presenting with acute coronary syndrome, particularly ST elevation myocardial infarction in this region is available. Hence, with respect to the high significance of early diagnosis and treatment of myocardial infarction in improving patients’ mortality and morbidity, we aimed to investigate the frequency and outcome of STEMI admissions and related factors in Heshmat cardiovascular diseases center in the north of Iran during the first three months of the pandemic.

**METHODOLOGY**

This cross-sectional study has aimed to determine the impact of the COVID-19 pandemic on the incidence of STEMI hospitalizations in the north of Iran. From February 20, 2020, to April 20, 2020, all the consecutive patients admitted with the diagnosis of STEMI to Heshmat hospital in Rasht (the only referral center for cardiovascular diseases in Guilan province) were recruited. The same data were collected for the equivalent period of the earlier year as the comparison group (February 20 to April 20, 2019). The study protocol was carried out according to the guidelines of the 2013 version Helsinki Declaration and was approved by the ethics committee of Guilan University of Medical Sciences with the code number: IR.GUMS.REC.1399.246.

In the present study, we focused on STEMI patients since they present with more severe symptoms, so they are more likely to ask for medical care services. At the same time, those with non-ST-elevation myocardial infarction (NSTEMI) may be able to endure less intense symptoms and tend to stay at home rather than reach out to hospitals. Also, STEMI is a simple unequivocal diagnosis that can easily be reached on the field.

Patients admitted to the hospital initially for STEMI who have also been diagnosed with COVID-19 were included. Subjects were excluded if the STEMI diagnosis was disproved in favor of another diagnosis (e.g., myocarditis). The diagnosis of acute STEMI was performed by an experienced interventional cardiologist and was defined as being characterized by ischemic myocardial symptoms and electrocardiographic changes compatible with STEMI (ST segment elevation in at least two anatomically contiguous leads; occurrence of pathological Q waves) in addition to dynamic changes of cardiac markers such as troponins or creatine-kinase myocardial band. The number of admitted STEMI cases, patients’ baseline demographic data, comorbidities such as diabetes (DM), hypertension (HTN), hyperlipidemia (HLP), smoking status, suspected COVID-19 infection, type of STEMI as well as the type of treatment (use of primary percutaneous coronary intervention (PPCI) or intravenous fibrinolytic), door to balloon and door to needle time, left ventricular ejection fraction (LVEF), data pertaining to coronary artery angiography and intervention (the number of involved arteries, culprit vessel, severity of involvement) and in-hospital mortality rate were collected and compared with the data from the non-COVID-19 group. All the information was gathered from the patients’ electronic files by a researcher of the team. After initial examinations and cardiology evaluations by expert cardiologists, patients underwent medical (fibrinolytic) or interventional therapy. Indications for PPCI were based upon the international guidelines.

Door to balloon time and door to needle time was defined as the time from arrival to the emergency department to successful wire crossing or the start of intravenous fibrinolytic, respectively.

At the beginning of the epidemic in our country, the RT-PCR technique was not available in this region to confirm the infection by SARS-COV-2. Since the current study was carried out in the same period, the diagnosis of COVID19 was performed based on clinical signs and symptoms according to the WHO guideline, and high resolution computed tomography patterns compatible with the disease.

Continuous variables were presented as mean and standard deviation (SD) and were compared using Independent Sample T-test, while categorical variables compared using Chi-square test. P values less than 0.05 were considered significant. All data analysis was done using IBM SPSS version 20.
RESULTS
Detailed information about patients’ characteristics is shown in Table 1. A total of 55 STEMI cases were admitted during February and April 2020, with a 40% reduction (Rate Ratio (RR): 0.60, 95% CI, 0.49-0.70) compared to the equivalent period in 2019 when 92 patients were registered for the same diagnosis (p<0.001). Out of 55 STEMI cases admitted to the hospital in 2020, 17 patients were diagnosed with concurrent COVID-19 infection.

Table 1. Demographic and clinical characteristics of patients with STEMI during and before COVID-19 pandemic

| Characteristics          | Before COVID-19 | During COVID-19 | P-value |
|--------------------------|-----------------|-----------------|---------|
| Total (N)                | 92              | 55              |         |
| Age (year)               | 60.83 ± 12.27   | 56.10 ± 8.16    | 0.012   |
| Gender                   |                 |                 |         |
| Male                     | 72(78.3)        | 47(85.5)        | 0.282   |
| Female                   | 20(21.7)        | 8(14.5)         |         |
| Risk factors             |                 |                 |         |
| Diabetes                 | 25(27.2)        | 6(10.9)         | 0.019   |
| Hypertension             | 39(42.4)        | 25(45.5)        | 0.717   |
| Dyslipidemia             | 25(27.2)        | 10(18.2)        | 0.215   |
| Family history of myocardial infarction | 20(21.7) | 7(12.7) | 0.172 |
| Smoking                  | 37(40.2)        | 25(45.5)        | 0.534   |
| Treatment*               |                 |                 |         |
| PPCI                     | 43(47.8)        | 41(75.9)        | 0.001   |
| Thrombolytic             | 47(52.8)        | 13(24.1)        |         |
| Angiography              |                 |                 |         |
| Single vessel disease    | 20(25.6)        | 15(27.8)        | 0.753   |
| Two vessel disease       | 31(39.7)        | 18(33.3)        |         |
| three vessel diseases    | 27(34.6)        | 21(38.9)        |         |
| Outcome                  |                 |                 |         |
| Dead                     | 4(4.4)          | 0(0)            | 0.298   |
| Alive                    | 88(95.6)        | 55(100)         |         |

P-value <0.05

* Data on treatment was missing in two patients in the before COVID-19 group and one in the COVID-19 group.

Compared with the pre-COVID-19 study group, STEMI patients hospitalized during the pandemic period were significantly younger (mean age: 56.10 in 2020 vs. 60.83 in 2019 p=0.012). The reduction of admission for females (RR: 0.4, 95% CI, 0.22-0.71) was higher than males (RR: 0.65, 95% CI, 0.54-0.77), but the result was not statistically significant (p=0.28). There was a 76% decrease in hospitalization of diabetic patients with the diagnosis of STEMI in 2020 compared to the equivalent period in 2019 (RR: 0.24 95% CI, 0.11-0.50, p=0.019). Moreover, there was no interaction of reduction of hospital admissions with history of HTN (36% decrease in patients with HTN [from 39 to 25 RR: 0.64, 95% CI, 0.49-0.82] vs. 44% reduction in patients with no history of HTN [from 53 to 30 RR: 0.56, 95% CI, 0.43-0.71]), HLP (60% decrease in patients with HLP [from 25 to 10, RR: 0.40, 95% CI, 0.23-0.68]) compared to 33% decrease in patients without HLP [RR: 0.67, 95% CI, 0.56-0.80]) and smoking status (33% reduction in smokers [from 37 to 25, RR: 0.67, 0.52-0.85] vs. 46% decrease in non-smokers [RR: 0.54,0.41-0.69]) between the two periods. The result of RR related to admission reduction is set out in Figure 1.

Figure 1: Rate ratios related to admission reduction in different groups

The present study regarding the types of treatments performed on patients demonstrated that in COVID-19 time, the percentage of PPCI referral was significantly higher than the previous year (47.8 % vs. 75.9 % p=0.001).

Figure 2: The mean of time to PPCI before and during COVID-19 era

Also, the mean of the door to balloon time during the COVID-19 era was significantly less than the pre-COVID-19 time (83.17 [SD= 35.26] vs. 106.30 [SD= 15.38], p<0.001) (Figure 2). No significant differences were found between the mean of EF of the patients in the COVID-19 era compared to the non-COVID studied population (mean of EF: 39.45% vs. 36.67%,...
respectively, p=0.067) (Figure 3). Finally, in-hospital death occurred in 4 (4.4%) of STEMI patients admitted before the COVID-19 time, while none of the COVID-19 periods studied cases died in hospital (p=0.298).

![Image](http://www.pakheartjournal.com/55/01/p5501067-01.jpg)

**Figure 3: The mean of ejection fraction before and during COVID-19 era**

**DISCUSSION**

This study found a dramatic decline in STEMI admissions during the COVID-19 pandemic compared to the previous year’s equivalent period in the north of Iran, which reflects those observed in earlier studies. A registry study in France noted a 24% decline in hospital admissions for STEMI between the periods directly before and after the lockdown, and according to the US and Spain cardiac catheterizations laboratories, 38% and 40% reduction in STEMI activation were reported, respectively. Recent data from northern California and a multicenter Italian registry indicated a striking decrease in acute MI hospitalizations during the COVID-19 era compared to the same period last year. Wilson SJ et al., evaluating the COVID-19 pandemic impact on STEMI presentations and outcome in the UK, reported a fall of about 50% in admissions. The reasons for the reduction in the STEMI admission rate are presumably multifactorial. The possible explanation might be the reluctance of patients to attend hospitals due to the great fear of exposure to SARS-COV-2 infection, particularly in those with atypical or less severe acute coronary diseases symptoms. As it is known, fear is a famous determinant of medical care-seeking avoidance and is strongly associated with epidemics. Additionally, this concern could have been intensified by the public health messages regarding encouraging people to stay at home. Another probable explanation may be the misinterpretation of MI symptoms (e.g., chest discomfort and dyspnea) as COVID-19 presentation, which also avoids asking for medical help in favor of self-quarantine. Moreover, lockdown and intense social isolation have resulted in decreased physical activity and work-related stress, which are considered as potential triggers of MI in high-risk patients. It is worth mentioning that improved hand hygiene and preventive protocols (e.g., masks and social distances) might also have contributed to a considerable reduction in the prevalence of other respiratory viral infections such as influenza, which has been previously reported as a strong trigger of MI in at-risk individuals. In a meta-analysis by Sofi F et al., it was revealed that contrary to what may have been expected, epidemiological measures and social policy parameters (e.g., lockdown measures) related to COVID-19 were not associated with the different incidence of STEMI hospitalization across countries. In contrast, the different organizations of emergency medicine programs and/or hospital operations during the pandemic may have played a role.

In our study, STEMI patients admitted to the hospital during the COVID-19 era were significantly younger than the previous year. In line with our study, according to the France registry, the decrease of MI admissions was greater in old patients (80 years and over). However, in some other inquiries, patients who were hospitalized in the COVID-19 era with MI diagnosis were reported to be older than the pre-COVID-19 reference group. Furthermore, we found a major decline in the admission of STEMI patients with a history of diabetes, hypertension, and hyperlipidemia compared to the non-COVID-19 period; nevertheless, except for diabetic patients, the differences were not statistically significant. These findings can be interpreted as a greater fear of being infected and having a worse clinical situation in older patients and those with comorbidities. It has been proposed that the COVID-19 pandemic leads to a high mortality rate among patients with comorbidities such as diabetes, hypertension, cardiovascular diseases, and chronic respiratory diseases. Albeit, in some previous studies, the admission rate reduction was of a similar magnitude across all subgroups in terms of the presence of comorbidities such as diabetes and hypertension.

In the current survey, medical delays (explained as the door to balloon time) were significantly shorter during the pandemic, and rates of PPCI performed on STEMI patients in the COVID-19 era were higher than the same period last year, which indicate that the efficacy of the care pathways and hospital strategies for STEMI patients have not been affected by the outbreak.
Collectively, no differences were observed in the number of STEMI in-hospital deaths during the pandemic compared to the reference period. Likewise, Mafham M et al. study demonstrated that no overall increase in in-hospital mortality had been observed among patients admitted with the acute coronary syndrome in the UK during the pandemic; however, it should be noted that our study focused on STEMI patients admitted in the COVID-19 era compared to the equivalent time in the previous year. In contrast, a number of previous studies reported a substantial increase in STEMI patients’ mortality rate in the COVID-19 period.\(^{(19,22)}\) This rather contradictory result may be due to the differences in study periods, population, or designs, and the fact that countries have been through various stages of the outbreak and have experienced different burdens of the pandemic at the time of their study.

The results of our study provide further support for the hypothesis that in the epidemic situation, acute MI patients may evade attending hospital emergencies or defer going, which can result in several detrimental consequences, including out-of-hospital deaths. MI patients seeking hospitals with delay or not reaching out for medical help could experience longer infarct, severe heart failure, and malignant arrhythmias. Accordingly, irrespective of the reasons, the reduced rate of acute MI admissions is worrisome and can rise to considerable cardiac complications.\(^{(7,20,21)}\)

Our study should be considered in the context of the following limitations. It was a single-center study investigating STEMI patients’ admissions rate in two months in the context of the general lockdown. At the beginning of the epidemic in our country, the RT-PCR technique was not available to confirm the infection by SARS-CoV-2. Regarding the interaction of MI admission with risk factors, it should be noted that in different years among people with the same risk factor, the prevalence of STEMI is comparable, which is likely but actually unknown. Moreover, as known from the literature, the lockdown carried potentially confounding factors (e.g., lower pollution, less physical activity), reducing the overall STEMI prevalence. Lastly, our sample size is relatively small but represents the data from the only referral cardiovascular diseases medical center of the Guilan province in the north of Iran.

**CONCLUSION**

In conclusion, this single-center observational study demonstrated a substantial decline in STEMI hospitalizations during the COVID-19 pandemic. No changes in overall in-hospital mortality or quality indicators were detected.

**AUTHORS' CONTRIBUTION:**

SN: Concept and design, data acquisition, interpretation, drafting, final approval, and agree to be accountable for all aspects of the work.
AS, FM, AV, SH, ER, RA, AFM, JK: Data acquisition, interpretation, drafting, final approval and agree to be accountable for all aspects of the work.

**Conflict of interest:** Authors declared no conflict of interest.

**REFERENCES**

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33.
2. Raccio A, Takian A, Sari AA, Olyaeemanesh A, Haghighi H, Aarabi M. COVID-19 pandemic and comparative health policy learning in Iran. Arch Iran Med. 2020;23(4):220-34.
3. Salimi R, Gomar R, Heshmati B. The COVID-19 outbreak in Iran. J Glob Health. 2020;10(1):101365.
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuan, China. Lancet. 2020;395(10223):497-506.
5. Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323(15):1488-94.
6. Kristofferson ES, Jahn SH, Thommessen B, Rønning OM. Effect of COVID-19 pandemic on stroke admission rates in a Norwegian population. Acta Neurol Scand. 2020;142(6):632-6.
7. Mesnier J, Cottin Y, Coste P, Ferrari E, Schiele F, Lemesle G, et al. Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in France: a registry study. Lancet Public Health. 2020;5(10):e536-e42.
8. Mafham MM, Spata E, Goldacre R, Gair D, Cumnow P, Bray M, et al. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. Lancet. 2020;396(10248):319-32.
9. Solomon MD, McNulty EJ, Rana JS, Leong TK, Lee C, Sung S-H, et al. The Covid-19 pandemic and the incidence of acute myocardial infarction. N Engl J Med. 2020;383(7):691-3.
10. Rangé G, Hakim R, Motreff P. Where have the ST-segment elevation myocardial infarctions gone during COVID-19 lockdown? Eur Heart J Qual Care Clin Outcomes. 2020;6(3):223-4.
11. Huet F, Prieur C, Schurtz G, Gerbaud E, Manzo-Silberman S, Vanzetto G, et al. One train may hide another: Acute cardiovascular diseases could be neglected because of the COVID-19 pandemic. Arch Cardiovasc Dis. 2020;113(5):303-7.
12. Nourazari R, Davis SR, Granovsky R, Austin R, Straff DJ, Joseph JW, et al. Decreased hospital admissions through emergency departments during the COVID-19 pandemic. Am J Emerg Med. 2021;42:203-10.
13. Hammad TA, Parikh M, Tashtish N, Lowry CM, Gorbev D, Forouzandeh F, et al. Impact of COVID-19 pandemic on ST-elevation myocardial infarction in a non-COVID-19 epicenter. Catheter Cardiovasc Interv. 2021;97(2):208-14.
14. Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259-60.
15. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77.
16. Welt FG, Shah PB, Aronow AE, Henry TD, Sherwood MW, et al. Catheterization laboratory considerations during the coronavirus (COVID-19) pandemic: from the ACC’s Interventional Council and SCAI. J Am Coll Cardiol. 2020;75(18):2372-5.
17. Organization WH. Use of chest imaging in COVID-19: a rapid advice guide, 11 June 2020. World Health Organization; 2020.
18. Piuhola J, Kerkelä R, Laine M, Andersen GØ, Ėrglis A, Kumsārs I, et al. Lower ST-elevation myocardial infarction incidence during COVID-19 epidemic in Northern Europe. Scand Cardiovasc J. 2020;54(6):358-60.
19. De Rosa S, Spaccarotella C, Basso C, Calabrò MP, Curcio A, Filardi PP, et al. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J. 2020;41(22):2083-8.
20. Mohammad MA, Koul S, Olivercrona GK, Götberg M, Tydén P, Rydberg E, et al. Incidence and outcome of myocardial infarction treated with percutaneous coronary intervention during COVID-19 pandemic. Heart. 2020;106(23):1812-8.
21. Rodríguez-Leor O, Cid-Álvarez B, de Prado AP, Rossello X, Ojeda S, Serrador A, et al. Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience. Revista Española de Cardiología (English Edition). 2020;73(12):994-1002.
22. Wilson SJ, Connolly MJ, Elghamry Z, Cosgrove C, Firoozi S, Lim P, et al. Effect of the COVID-19 pandemic on ST-segment–elevation myocardial infarction presentations and in-hospital outcomes. Circ Cardiovasc Inter. 2020;13(7):e009438.
23. Sofi F, Dinu M, Reboldi G, Stracci F, Pedretti RF, Valente S, et al. Worldwide differences of hospitalization for ST-segment elevation myocardial infarction during COVID-19: A systematic review and meta-analysis. Int J Cardiol. 2021;347:89-96.
24. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.
25. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13.

Address for Correspondence:
Dr. Jalal Kheirkhah, Associate Professor of Cardiology, Cardiovascular Diseases Research Center, Department of Cardiology, Heshmat Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Guilan Province, Iran.
Email: a.fakhr.md@gmail.com